| Browse All

BiomX Inc. (PHGE)

Healthcare | Biotechnology | Dover, United States | NYSE American
1.84 USD -0.13 (-6.599%) ⇩ (April 17, 2026, 4 p.m. EDT)
After hours: 1.83 -0.01 (-0.010%) ⇩ (April 17, 2026, 7:56 p.m. EDT)

Short-term: ★☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 11, 2026, 4:01 p.m. EDT

PHGE is a highly volatile stock with negative fundamentals and a poor price trajectory. The recent price history shows a significant decline, and the stock is currently trading near its 52-week low. The stock's fundamentals are weak, with negative earnings and a low market cap. The stock has no dividend history, and the forecasting model indicates a low probability of a positive price movement in the short term. Investors should avoid this stock unless they are looking for a high-risk, high-reward opportunity.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoETS ✓0.572756
MSTL0.577395
AutoARIMA1.264602
AutoTheta1.297074

Forecast horizon: 45 days | Selected: AutoETS

Forecast Reliability
Score 80%
H-stat 0.38
Ljung-Box p 0.000
Jarque-Bera p 0.388
Excess Kurtosis -0.58
Attribute Value
Sector Healthcare
Market Cap 16,130,390
Forward P/E -0.14
Beta 1.70
Website https://www.biomx.com

Info Dump

Attribute Value
52 Week Change -0.81010216
Address1 850 New Burton Road
Address2 Suite 201
All Time High 2,261.0
All Time Low 1.5
Ask 1.84
Ask Size 100
Average Daily Volume10 Day 262,970
Average Daily Volume3 Month 1,057,375
Average Volume 1,057,375
Average Volume10Days 262,970
Beta 1.702
Bid 1.82
Bid Size 100
Book Value -12.499
City Dover
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 1.84
Current Ratio 0.874
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 1.9
Day Low 1.7
Display Name BiomX
Earnings Call Timestamp End 1,755,086,400
Earnings Call Timestamp Start 1,755,086,400
Earnings Timestamp End 1,778,785,200
Earnings Timestamp Start 1,778,785,200
Ebitda -27,998,000
Ebitda Margins 0.0
Enterprise To Ebitda -0.665
Enterprise Value 18,625,414
Eps Current Year -5.85
Eps Forward -12.98
Eps Trailing Twelve Months -37.05
Esg Populated 0
Exchange ASE
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 4.73768
Fifty Day Average Change -2.8976798
Fifty Day Average Change Percent -0.61162424
Fifty Two Week Change Percent -81.010216
Fifty Two Week High 14.706
Fifty Two Week High Change -12.866
Fifty Two Week High Change Percent -0.87488097
Fifty Two Week Low 1.5
Fifty Two Week Low Change 0.34000003
Fifty Two Week Low Change Percent 0.22666669
Fifty Two Week Range 1.5 - 14.706
Financial Currency USD
First Trade Date Milliseconds 1,552,483,800,000
Float Shares 1,121,250
Forward Eps -12.98
Forward P E -0.14175655
Free Cashflow -14,071,500
Full Exchange Name NYSE American
Full Time Employees 20
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.35863
Held Percent Institutions 0.04092
Implied Shares Outstanding 8,766,516
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,764,028,800
Last Split Factor 1:19
Long Business Summary BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company's phage-based therapies include fixed cocktail therapy, which involves developing a single product containing a fixed number of selected phages to cover a range of bacterial strains; and personalized therapy, which involves developing a large library of phages from which single optimal phages are personally matched to treat specific patients. It develops BX011, a fixed multi-phage cocktail, which is in Phase 2a trial for the treatment of diabetic foot infections; and BX211, a phage therapy, which is in Phase 2 trial for the treatment of diabetic foot osteomyelitis. BiomX Inc. was founded in 2015 and is based in Dover, Delaware.
Long Name BiomX Inc.
Market us_market
Market Cap 16,130,390
Market State CLOSED
Max Age 86,400
Message Board Id finmb_430935769
Most Recent Quarter 1,767,139,200
Net Income To Common -36,199,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 16,130,389
Number Of Analyst Opinions 1
Open 1.92
Operating Cashflow -26,390,000
Operating Margins 0.0
Payout Ratio 0.0
Post Market Change -0.010100007
Post Market Change Percent -0.5489134
Post Market Price 1.8299
Post Market Time 1,776,470,207
Previous Close 1.97
Price Eps Current Year -0.31452993
Price Hint 4
Price To Book -0.14721179
Profit Margins 0.0
Quick Ratio 0.701
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.13
Regular Market Change Percent -6.59898
Regular Market Day High 1.9
Regular Market Day Low 1.7
Regular Market Day Range 1.7 - 1.9
Regular Market Open 1.92
Regular Market Previous Close 1.97
Regular Market Price 1.84
Regular Market Time 1,776,456,000
Regular Market Volume 180,718
Return On Assets -0.78852
Return On Equity -3.1689599
Sand P52 Week Change 0.36506534
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 8,766,516
Shares Percent Shares Out 0.013099999
Shares Short 86,010
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 96,310
Short Name BiomX Inc.
Short Percent Of Float 0.013099999
Short Ratio 1.04
Source Interval 15
State DE
Symbol PHGE
Target High Price 304.0
Target Low Price 304.0
Target Mean Price 304.0
Target Median Price 304.0
Total Cash 4,360,000
Total Cash Per Share 2.736
Total Debt 1,436,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -37.05
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 6.69727
Two Hundred Day Average Change -4.85727
Two Hundred Day Average Change Percent -0.72526115
Type Disp Equity
Volume 180,718
Website https://www.biomx.com
Zip 19,904